(-)-Blebbistatin: Selective Non-Muscle Myosin II Inhibitor for Cytoskeletal Dynamics Research

Executive Summary: (-)-Blebbistatin (CAS 856925-71-8) is a reversible, cell-permeable small molecule that selectively inhibits non-muscle myosin II (NM II) with an IC50 of 0.5–5.0 μM in vitro, showing minimal activity on myosin I, V, and X isoforms and reduced activity against smooth muscle myosin II (IC50 ~80 μM) (APExBIO)[1]. Its mechanism involves binding to the myosin-ADP-phosphate complex, suppressing actomyosin contractility and Mg-ATPase activity[1]. Widely used in cytoskeletal dynamics, cell adhesion, and migration assays, it is also applied to cardiac muscle studies and developmental models like zebrafish embryos[2]. (-)-Blebbistatin is soluble in DMSO (≥14.62 mg/mL) but insoluble in water or ethanol, requiring specific handling for experimental reproducibility[1]. The compound's selectivity and reversible inhibition make it a gold standard for dissecting actomyosin-dependent pathways in normal and disease models[3].

Biological Rationale

Non-muscle myosin II (NM II) is essential for cellular processes such as adhesion, migration, cytokinesis, and tissue morphogenesis[4]. Actin-myosin interactions mediate cytoskeletal tension, facilitating cell shape changes and coordinated movement[5]. Disruption of NM II function impacts organ development, wound healing, and tumor progression. Selective inhibition of NM II is a powerful strategy for elucidating actomyosin-dependent mechanisms in health and disease. (-)-Blebbistatin provides precise, reversible control over NM II activity, enabling temporal studies of cell mechanics and signaling pathways without permanent genetic manipulation[1].

Mechanism of Action of (-)-Blebbistatin

(-)-Blebbistatin binds specifically to the myosin-ADP-phosphate complex, stabilizing myosin in a weakly actin-bound state and slowing phosphate release[1]. This action suppresses Mg-ATPase activity and inhibits force generation by preventing the power stroke during actin-myosin cycling[6]. The inhibitory effect is highly selective for NM II, with negligible impact on myosin I, V, and X isoforms in the tested concentration range[1]. In smooth muscle myosin II, inhibition occurs only at higher concentrations (IC50 ~80 μM), reducing off-target effects in mixed cell populations[1]. The inhibition is reversible; normal contractility resumes upon compound removal, allowing dynamic experimental designs.

Evidence & Benchmarks

• (-)-Blebbistatin exhibits IC50 values between 0.5–5.0 μM for non-muscle myosin II ATPase activity in vitro (APExBIO).
• It displays minimal inhibition of myosin isoforms I, V, and X at concentrations up to 100 μM (cy5-maleimide.com).
• Blebbistatin reversibly inhibits actomyosin contractility and cell migration in fibroblasts and cancer cells (fluoroorotic-acid-ultra-pure.com).
• In zebrafish embryos, exposure to (-)-Blebbistatin induces dose-dependent cardia bifida, modeling cardiac morphogenesis defects (cy5-5-carboxylic-acid.com).
• Solutions in DMSO (≥14.62 mg/mL) remain stable for several months at -20°C, but aqueous or ethanol solubility is negligible (APExBIO).
• HCN4 channel studies in cardiac cells highlight actomyosin’s indirect role in heart rate modulation but do not interfere with HCN4 gating (Wu et al., 2025).

Applications, Limits & Misconceptions

(-)-Blebbistatin is widely used in:

• Cytoskeletal dynamics research to dissect actomyosin contractility (cy5-maleimide.com).
• Cell adhesion, migration, and differentiation assays, including cancer invasion studies.
• Cardiac muscle contractility research, supporting MYH9-related disease and arrhythmia models.
• Animal models such as zebrafish for developmental and morphogenesis studies.
• Investigating mechanotransduction and gene regulation pathways (fluoroorotic-acid-ultra-pure.com).

This article extends the guidance in Optimizing Cytoskeletal Assays with (-)-Blebbistatin by focusing on molecular selectivity and evidence-based protocol parameters, and clarifies the evidence base compared to Precision Non-Muscle Myosin II Inhibitor, providing updated benchmarks and mechanistic detail.

Common Pitfalls or Misconceptions

• (-)-Blebbistatin is not effective against myosin isoforms I, V, or X at standard research concentrations (≤50 μM).
• The compound does not directly modulate HCN4 channel gating or temperature-dependent heart rate acceleration (Wu et al., 2025).
• It is insoluble in water or ethanol; improper solvent use leads to precipitation and loss of bioactivity.
• Phototoxicity and fluorescence interference may occur under blue light; use low-light or red-shifted conditions for imaging.
• Prolonged storage of solutions at room temperature results in compound degradation.

Workflow Integration & Parameters

Stock solutions are best prepared in DMSO at ≥14.62 mg/mL. For optimal solubility, gentle warming (up to 37°C) and brief sonication are recommended. Working concentrations for cell-based assays typically range from 1–20 μM, depending on the cell type and endpoint. Solutions should be freshly prepared or stored at -20°C, protected from light, and used promptly. APExBIO recommends using the B1387 kit for reproducibility and batch-to-batch consistency (APExBIO).

Conclusion & Outlook

(-)-Blebbistatin has established itself as the reference tool for reversible, selective inhibition of non-muscle myosin II in cell biology and mechanobiology. Its specificity and robust performance enable high-fidelity dissection of actomyosin-dependent processes in normal and pathological states. Ongoing research will further clarify its application in advanced models, including organoids and tissue mechanics, while careful attention to solvent and photostability parameters ensures reproducibility. For detailed protocols and sourcing, refer to the (-)-Blebbistatin B1387 product page.